The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial.
S. P. Lerner
Research Funding - Pfizer
T. Powles
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
N. M. Hahn
No relevant relationships to disclose
T. Gardner
No relevant relationships to disclose
L. Cheng
No relevant relationships to disclose
J. Green
No relevant relationships to disclose
D. Berney
No relevant relationships to disclose
D. Taber
No relevant relationships to disclose
J. Landgraf
No relevant relationships to disclose
S. S. Shen
No relevant relationships to disclose
G. Sonpavde
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb